Envlo is named as an intervention in 3 current clinical trials in our South Korea register. 1 is recruiting patients now. All registered phases are Observational. The lead sponsor is Daewoong Pharmaceutical Co. LTD. The most-studied condition is Diabetes Mellitus, Type 2.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Evaluation of Enavogliflozin's Efficacy and Safety in Type II Diabetes With Hypertension or Dyslipidemia
NCT06647888 · ClinicalTrials.gov ↗ · Diabetes Mellitus, Type 2
|
Observational | Recruiting | Daewoong Pharmaceutical Co. LTD | South Korea |
|
To Evaluate the Efficacy and Safety of Envlo Tablet or Envlomet SR Tablet in Patients With Type II Diabetes Mellitus
NCT05926414 · ClinicalTrials.gov ↗ · Diabetes Mellitus, Type 2
|
Observational | Active, closed | Daewoong Pharmaceutical Co. LTD | South Korea |
|
Registry Study to Determine the Effectiveness and Safety of Weight Loss With Enavogliflozin in Patients With Type 2 Diabetes Mellitus
NCT06427083 · ClinicalTrials.gov ↗ · Type 2 Diabetes Mellitus
|
Observational | Active, closed | Daewoong Pharmaceutical Co. LTD | South Korea |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Daewoong Pharmaceutical Co. LTD | 3 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in South Korea | 3 | 1 |
A trial with sites in more than one country appears in each of those registers.
3 current trials in our South Korea register name Envlo as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 1 of the 3 trials is recruiting: 1 with sites in South Korea. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
The lead sponsor is Daewoong Pharmaceutical Co. LTD. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Envlo works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Envlo works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Envlo (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.